Full-Time

Director/Senior Director

Clinical Data Management

Confirmed live in the last 24 hours

Beam Therapeutics

Beam Therapeutics

501-1,000 employees

Develops precision genetic medicines using base editing

No salary listed

Expert

Cambridge, MA, USA

Onsite presence is preferred.

Category
Data Management
Data & Analytics
Required Skills
Google Cloud Platform
Requirements
  • Bachelor’s or master’s degree in a scientific or health-related field with 15+ years of experience; level will be commensurate with experience
  • Minimum of 14 years of experience in clinical data management within the pharmaceutical or CRO, with experience in managing Phase I, II and III studies, from start-up through closure for multiple clinical studies
  • At least 4 years of management experience with strong organizational, leadership and project management skills
  • Extensive knowledge and experience in study start-up, study conduct and study closeout
  • Proficiency with EDC systems including Oracle Inform and/or Medidata Rave, and expertise in CDASH/CDISC standards, GCP/ICH guidance, and relevant FDA regulations
  • Experience developing reports using J-Review and/or other CDM reporting tools
  • Prior experience with IND filings and NDA/BLA submission is highly desirable
  • Highly organized, detail-oriented, and equipped with strong analytical and problem-solving skills
  • Self-motivated, with the ability to work independently and collaborate effectively with colleagues and vendors
  • Excellent verbal and written communication skills are essential
  • Proven ability to prioritize and manage timelines while adapting to shifting priorities within a fast-paced company environment
Responsibilities
  • Lead the Clinical Data Management (CDM) function, collaborating closely with cross-functional teams to oversee all data management deliverables and timelines for Beam clinical trials
  • Oversee CRO data managers and manage data management contractors, providing guidance and oversight to ensure timely and high-quality execution of the CDM activities across all Beam clinical trials.
  • Develop, implement and maintain CDM SOPs and working instructions, ensuring consistency, regulatory compliance and best practices across the department.
  • Serve as the primary point of contact for data management, liaising with CROs, third-party data vendors, and internal stakeholders to ensure smooth communication and alignment.
  • Lead data management activities during the study start-up and throughout the trial lifecycle, activities including but not limited to: CRF design, cross- functional CRF review, edit checks specification review and approval, database setup , user acceptance testing, CRF completion guidelines review and approval, CRO data management plan review and approval, external data transfer specifications and other essential documentations review and approval, vendor data reconciliation and SAE reconciliation oversight, data review and data cleaning oversight.
  • Oversee CRO’s ongoing review and cleaning of clinical data, which including EDC data review, vendor data review and reconciliation, supporting study deliverables.
  • Coordinate and facilitate internal cross-functional teams data review activities to ensure data quality and integrity, present data management activities progress, interim data cleaning metrics and final reports to internal teams and stakeholders, ensuring transparency and supporting data-driven decision-making.
  • Manage the database lock process and ensure proper archiving of study data in compliance with regulatory requirements.
  • Provide expertise on CDASH and CDISC data standards, collaborating with Statistical Programming to ensure accurate SDTM mapping.
  • Lead GCP inspection readiness efforts, acting as the primary point of contact for data management during regulatory inspections and ensuring the department is prepared for audits.
Desired Qualifications
  • Experience and knowledge of gene/cell therapy and/or rare disease are desirable
  • Being able to come onsite on a regular basis is preferred

Beam Therapeutics develops precision genetic medicines using a technique called base editing, which allows for precise changes to the genetic code to correct mutations that lead to serious diseases. Their primary focus is on treating genetic disorders, such as sickle cell disease, with the aim of providing lifelong cures instead of temporary solutions. The company invests significantly in research and development to create new therapies and generates revenue through partnerships, licensing agreements, and potential commercialization of their treatments after regulatory approval. Beam Therapeutics distinguishes itself from competitors by emphasizing a values-driven approach, a strong team of experts, and a commitment to rigorous scientific development. The ultimate goal of the company is to advance genetic medicine to improve the lives of patients suffering from genetic disorders.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Cambridge, Massachusetts

Founded

2017

Simplify Jobs

Simplify's Take

What believers are saying

  • Beam raised $500 million to advance its R&D and expand its genetic medicine pipeline.
  • Successful Phase 1/2 trial for BEAM-302 shows potential beyond sickle cell disease.
  • Partnership with Eli Lilly highlights commercial potential and industry confidence in Beam's technology.

What critics are saying

  • Increased competition from CRISPR Therapeutics could impact Beam's market share.
  • New CFO appointment may lead to transitional challenges or shifts in financial strategy.
  • $500 million equity offering may dilute existing shareholders' value, causing dissatisfaction.

What makes Beam Therapeutics unique

  • Beam Therapeutics uses base editing, a safer alternative to traditional CRISPR methods.
  • The company focuses on lifelong cures for genetic disorders, not just symptom management.
  • Beam's technology targets single base changes without causing double-stranded DNA breaks.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
GlobeNewswire
Mar 10th, 2025
Beam Therapeutics Announces Pricing of Underwritten Offering

CAMBRIDGE, Mass., March 10, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic...

Benzinga
Mar 10th, 2025
Beam Therapeutics Reports Data, Raises $500M

Beam Therapeutics announced promising initial safety and efficacy data from its Phase 1/2 trial of BEAM-302 for treating alpha-1 antitrypsin deficiency (AATD). The trial showed BEAM-302 was well tolerated and led to dose-dependent correction of the disease-causing mutation. Beam plans to continue the trial and report further data in 2025. Additionally, Beam raised $500 million through an equity offering. BEAM stock was down 3.44% at $27.50 in premarket trading.

GlobeNewswire
Dec 6th, 2024
Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer

CAMBRIDGE, Mass., Dec. 06, 2024 (GLOBE NEWSWIRE) - Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the appointment of Sravan K. Emany as chief financial officer (CFO), effective December 19, 2024.

CityBiz
Jul 15th, 2024
Beam Therapeutics Chief Financial Officer Terry-Ann Burrell to Retire

CAMBRIDGE, Mass., July 15, 2024 (GLOBE NEWSWIRE) - Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that its chief financial officer, Terry-Ann Burrell, will be leaving the company effective August 9, 2024 to pursue a new opportunity as vice chairman of investment banking at JPMorgan Chase.

Securities.io
May 21st, 2024
10 Rare Diseases Specialist Stocks

Rare Diseases – Curing The IncurableWhile not entirely solved, a lot of major deadly illnesses that have plagued humanity have become more manageable over the last century, from bacterial (antibiotics) and viral (vaccines) infections to diabetes (insulin).There is, however, a wide array of rare diseases which are still mostly incurable. Most of the time, this is because these diseases are not caused by an external threat, but by a biological dysfunction inside the very cells of the patient. This is quickly changing, thanks to progress in biosciences.On one hand, with the human genome sequenced and much more advanced analytical methods, scientists can finally understand what are the root causes of rare diseases. Even AI is now helping interpret the data and provide new insights .On the other hand, new technologies like gene editing open the possibility of fixing deficient cells or organs, restoring normal function.Rare diseases each affect less than 1 in 2,000 people, with more than 6000 different rare diseases. Despite their individual rarity, together, they affect around 4% of the population, with as many as 30 million people in just Europe .3/4 of rare diseases affect children, 72% are genetic in origin, and it takes on average 5 years for rare disease patients to get a diagnosis.CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) is a recently discovered tool for genetic editing. It allows for very precise and directed gene editing, and its discoverers have won the 2020 Nobel Prize .What sets CRISPR Therapeutics apart is the all-star team of founders, including Dr